pipobroman has been researched along with Cancer, Second Primary in 5 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 5.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| "Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration." | 1.51 | Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. ( Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K, 2019) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 1.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbui, T | 1 |
| Ghirardi, A | 1 |
| Masciulli, A | 1 |
| Carobbio, A | 1 |
| Palandri, F | 1 |
| Vianelli, N | 1 |
| De Stefano, V | 1 |
| Betti, S | 1 |
| Di Veroli, A | 1 |
| Iurlo, A | 1 |
| Cattaneo, D | 1 |
| Delaini, F | 1 |
| Bonifacio, M | 1 |
| Scaffidi, L | 1 |
| Patriarca, A | 1 |
| Rumi, E | 1 |
| Casetti, IC | 1 |
| Stephenson, C | 1 |
| Guglielmelli, P | 1 |
| Elli, EM | 1 |
| Palova, M | 1 |
| Bertolotti, L | 1 |
| Erez, D | 1 |
| Gomez, M | 1 |
| Wille, K | 1 |
| Perez-Encinas, M | 1 |
| Lunghi, F | 1 |
| Angona, A | 1 |
| Fox, ML | 1 |
| Beggiato, E | 1 |
| Benevolo, G | 1 |
| Carli, G | 1 |
| Cacciola, R | 1 |
| McMullin, MF | 1 |
| Tieghi, A | 1 |
| Recasens, V | 1 |
| Marchetti, M | 1 |
| Griesshammer, M | 1 |
| Alvarez-Larran, A | 1 |
| Vannucchi, AM | 1 |
| Finazzi, G | 1 |
| Stein, BL | 1 |
| Moliterno, AR | 1 |
| Tiu, RV | 1 |
| Petti, MC | 1 |
| Spadea, A | 1 |
| Avvisati, G | 1 |
| Spadea, T | 1 |
| Latagliata, R | 1 |
| Montefusco, E | 1 |
| Cosenza, M | 1 |
| Malagnino, F | 1 |
| Randi, ML | 2 |
| Fabris, F | 2 |
| Girolami, A | 2 |
1 review available for pipobroman and Cancer, Second Primary
| Article | Year |
|---|---|
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
4 other studies available for pipobroman and Cancer, Second Primary
| Article | Year |
|---|---|
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile | 2019 |
Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Female; Follow-Up | 1998 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |